David Hagerty
About
In The Last Decade
David Hagerty
33 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Immunology 1.6k
- Rheumatology 1.3k
- Transplantation 882
- Surgery 739
- Epidemiology 709
Countries citing papers authored by David Hagerty
This map shows the geographic impact of David Hagerty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hagerty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hagerty more than expected).
Fields of papers citing papers by David Hagerty
This network shows the impact of papers produced by David Hagerty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hagerty. The network helps show where David Hagerty may publish in the future.
Co-authorship network of co-authors of David Hagerty
This figure shows the co-authorship network connecting the top 25 collaborators of David Hagerty. A scholar is included among the top collaborators of David Hagerty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hagerty. David Hagerty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease | 0 |
| 2 | 75 | |
| 3 | The Calm App as an Adjunct to Physical Therapy for Chronic Neck and Shoulder Pain | 1 |
| 4 | 27 | |
| 5 | 107 | |
| 6 | 12 | |
| 7 | 84 | |
| 8 | 62 | |
| 9 | 142 | |
| 10 | Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition breakdown → | 920 |
| 11 | Costimulation Blockade with Belatacept in Renal Transplantation breakdown → | 628 |
| 12 | Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties breakdown → | 549 |
| 13 | Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig breakdown → | 807 |
| 14 | 15 | |
| 15 | 56 | |
| 16 | 48 | |
| 17 | 48 | |
| 18 | 2 | |
| 19 | 1 | |
| 20 | 20 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.